Home / World Marketplace / Archive by category Global Health & Biotech (Page 17)

Archive by category Global Health & Biotech

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial1 Accelerated approval follows Priority Review and Breakthrough Therapy Designation granted by the U.S. FDA for the treatment of patients with HER2 (ERBB2)-mutant advanced non-small cell [...]

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

SHANGHAI, Aug. 08, 2025 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“sNDA”) for toripalimab (trade name: TUOYI®) in combination with disitamab vedotin, an antibody-drug conjugate (“ADC”) [...]

WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation

NEW YORK, Aug. 07, 2025 (Korea Bizwire) – WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced that longserving WW board member Julie Rice, the entrepreneur and brand builder best known for co-founding SoulCycle, is joining WeightWatchers as Chief Experience Officer. As WeightWatchers evolves its holistic [...]

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP. CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial.1,2 Often underappreciated and less recognized, negative symptoms impact [...]

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

VERO BEACH, Fla., Aug. 07, 2025 (Korea Bizwire) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives. We believe [...]

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL [...]

Carestream Announces Improvements to Affordable, Digital-Ready Horizon X-ray System

New Floating Table Will Provide Enhancements to Positioning, Efficiency, and Image Quality Rochester, N.Y., Aug. 06, 2025 (Korea Bizwire) – Carestream Health today announced the addition of a new, six-way floating table for its Horizon X-ray System—helping provide significant benefits to patient positioning, workflow efficiency, and overall image quality. The ergonomic table helps elevate [...]

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine [...]

EVIDENT to Acquire Pramana, Inc

Expanded product offering propels digital pathology from simply creating images to generating new insights for pathologists WALTHAM, Mass., Aug. 04, 2025 (Korea Bizwire) — Evident announces a definitive agreement to acquire Pramana, Inc., a leading manufacturer of digital pathology solutions. Pramana’s cutting-edge autonomous whole slide imaging technologies, combined with Evident’s longstanding leadership in clinical microscopy [...]

Indonesia’s Ministry of Health and Philips to deliver nationwide coverage of advanced image-guided therapy systems in Indonesia, expanding access to cardiac, stroke and cancer care in all 38 provinces

July 29, 2025 Long-term multiyear agreements will see Philips installing its advanced Azurion image-guided therapy systems nationwide across all provinces, including rural and remote areas Initiative brings minimally invasive care to millions of cardiac, stroke and cancer patients in Indonesia Combines cutting-edge treatment technology, services and training to strengthen Indonesia’s health infrastructure Amsterdam, the Netherlands [...]